About Us
About ProMab Biotechnologies, Inc.
Founded in 2001., ProMab Biotechnologies develops and commercializes recombinant proteins, antibodies, and engineered cell lines through the integration of bioinformatics, molecular biology, protein expression, purification techniques, gene cloning, microbiology, and immunology, using novel high-throughput technologies. ProMab provides its proprietary proteins, engineered cell lines, and antibodies to deliver innovative research and diagnostic products, as well as services for the global biomedical research community through collaborations, partnerships, and joint ventures with other biotechnology and bio-reagent companies. ProMab has also developed a novel mRNA lipid nanoparticle (mRNA-LNP) platform for ready-to-use reagents and custom research services to advance the current offerings and expand to more fields of research. ProMab is on target to be one of the leading suppliers of bio-reagents in the twenty-first century and is committed to improving human health with a focus on the field of immunotherapy, specifically CAR-T/NK cell technologies. Utilizing nearly two decades of experience generating highly specific and potent monoclonal antibodies, our success in CAR-T/NK development led us to become the first CAR-T CRO in the world.
Key Products & Services
Products
Services
Publications
HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth
Hu L, Zhang S, Sienkiewicz J, Zhou H, Berahovich R, Sun J, Li M, Ocampo A, Liu X, Huang Y, Harto H, Xu S, Golubovskaya V, Wu L. Vaccines (Basel). 2024 Jul 21; 12(7):808.
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo
Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, Harto H, Xu S, Berahovich R, Wu L. Int J Mol Sci. 2023 Aug 29; 24(17):13364.
Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth
Wu L, Huang Y, Sienkiewicz J, Sun J, Guiang L, Li F, Yang L, Golubovskaya V. Cancers (Basel). 2022 May 20; 14(10):2518.
Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Biomedicines. 2021 Oct 9; 9(10):1422.
PLAP -CAR T cells mediate high specific cytotoxicity against colon cancer cells
Li X, Berahovich R, Zhou H, Liu X, Li F, Xu S, Wei Y, Ouaret D, Bodmer W, Wu L, Golubovskaya V. Front Biosci (Landmark Ed). 2020 Jun 1; 25(9):1765-1786.
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Berahovich R, Liu X, Zhou H, Tsadik E, Xu S, Golubovskaya V, Wu L. Cancers (Basel). 2019 Apr 30; 11(5):602.